Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $3.00B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.44M
Average 1.71M
Returns on capital
Dyne Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-45.9%
avg -48.4%
ROIC
-41.0%
avg -52.6%
ROA
-37.6%
avg -43.8%
Analysis
ROA is currently the strongest return metric at -37.6% versus its period average of -43.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
John G. Cox | Chief Executive Officer, President & Director | USD 1.14M | 63 | — | — |
Johanna Friedl-Naderer | Chief Commercial Officer | USD 842.75K | 58 | 152.90K | 0.09% |
Douglas Kerr | Head of Research & Development and Chief Medical Officer | USD 748.07K | 59 | 12.00K | <0.01% |
Oxana Beskrovnaya | Chief Innovation Officer | USD 740.48K | 65 | 195.84K | 0.12% |
Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | USD 726.89K | 58 | — | — |
Alessandro Martuscelli | Chief Legal Officer | — | — | — | — |
James Bilotta | Chief Digital & Information Officer | — | — | — | — |
Debra Feldman | Chief Regulatory Affairs Officer | — | 55 | — | — |
Lucia Celona | Chief Human Resource Officer | — | 60 | — | — |
Rajesh Manchanda | Chief Technical Officer | — | 59 | — | — |
Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 20, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$314,840.00
Sells
122
$168.62M
Net Transaction Value
−$168.30M
Net selling
Most Active
Rhodes Jason P
79 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 2, 26Oct 2, 2026 | Posner Brian S Direct | Buy | $40K$40,000.00 |
| Sep 8, 26Sep 8, 2026 | Kerr Douglas Direct | Sell | $24.4K$24,355.20 |
| Sep 8, 26Sep 8, 2026 | Cox John Direct | Sell | $106.8K$106,823.04 |
| Sep 8, 26Sep 8, 2026 | Friedl-Naderer Johanna Direct | Sell | $3.5K$3,492.80 |
| Sep 4, 26Sep 4, 2026 | Kerr Douglas Direct | Sell | $91.2K$91,190.75 |
| Sep 4, 26Sep 4, 2026 | Friedl-Naderer Johanna Direct | Sell | $21.9K$21,915.00 |
| Aug 14, 26Aug 14, 2026 | Rhodes Jason P Indirect | Sell | $8.1M$8,061,625.00 |
| Aug 14, 26Aug 14, 2026 | Rhodes Jason P Indirect | Sell | $34M$33,991,850.00 |
| Aug 14, 26Aug 14, 2026 | Rhodes Jason P Indirect | Sell | $12M$11,959,425.00 |
| Aug 13, 26Aug 13, 2026 | Kerr Douglas Direct | Sell | $40.9K$40,891.68 |
1–10 of 130
Summary
Insiders reported 8 buys worth $314,840.00 and 122 sells worth $168.62M over the last 12 months. That adds up to net selling of $168.30M. Rhodes Jason P was the most active insider with 79 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Dyne Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about DYN's management, answered from reported figures.
Who manages DYN?
Dyne Therapeutics, Inc. (DYN) lists 11 active executives. The top listed executive is Douglas Kerr, Head of Research & Development and Chief Medical Officer.
Are DYN insiders buying or selling?
Recent insider activity shows net selling of $132.49M.
Continue the stock analysis
Jump to another research area for this company.